Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Jul 28 - Aug 2
Rodriguez 2025 (EHR, n=125,474): 1-year discontinuation 64.8% in non-diabetics vs 46.5% in type 2 diabetes
The initial findings were so impressive that some researchers suggested BPC-157 could be the prototype of a new class of organoprotective agents. There were still many unanswered questions, though: Would other studies replicate these findings
Phase 2 trial data (Jastreboff et al., NEJM 2023) demonstrated average weight reductions of approximately 1724% over 48 weeks notably higher than currently approved GLP-1 receptor agonists such as semaglutide, though direct comparisons are limited by differences in trial populations and designs
Dec 14, 2025 BPC-157 is one of the most talked-about peptides in the biohacking world
Reconstitution AOD 9604 typically comes as lyophilized powder requiring reconstitution with bacteriostatic water
Health history, medications, pregnancy status, breastfeeding, and treatment goals all matter
